Merck MRK -3.79% & Co. and Ridgeback Biotherapeutics LP said a final analysis of their experimental Covid-19 pill found the drug less effective than an early look, prompting U.S. health regulators to continue a staff review of the drug’s application days before an outside panel meets.
The Food and Drug Administration made public Friday their initial review of the drug’s application, including an analysis of clinical-trial data for the drug, molnupiravir. Agency staff said the drug was effective at reducing the risk of hospitalization and death, but they didn’t take a position on whether the agency should authorize the drug. The agency also said no major safety concerns turned up in late-stage testing.
The FDA said it is still conducting its review of molnupiravir, after the companies told the agency earlier this week the pill was 30% effective in a final analysis of the late-stage study results. After taking an early look at results, the companies had reported in October that molnupiravir was 50% effective.
Molnupiravir, and another experimental antiviral from Pfizer Inc. PFE 6.11% that is also under FDA review, promise to fill a big gap in Covid-19 treatment for a pill that people could easily take at home to keep them out of the hospital.
Go here to read more, but the real story is that they don’t make any money on the cure for Covid, Ivermectin, also made by Merck but out of patent (or HCQ). It has worked in India, Japan and in African countries where the jab wasn’t possible, or as effective as a political weapon of power and control.
Click on Covid in my tag cloud and you’ll see endless facts of the makers of the mRNA jab saying that it is a bioweapon and the facts that back up Ivermectin’s efficacy.